Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastrointestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.

Abstract: The present invention provides bradykinin-B1 antagonists of the formula in which A, Ar, G, Q, R1 and R4 are as defined in claim 1, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts with organic or inorganic acids or bases having useful properties, their preparation, medicaments comprising the pharmacologically effective compounds, their preparation and their use.

Abstract: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solution concentrates.

Abstract: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solutions.

Abstract: The invention relates to oxaliplatin solutions that also preferably contain sulfuric acid, phosphoric acid, methane sulfonic acid, ethane sulfonic acid, or para-toluene sulfonic acid. The solutions according to the invention are distinguished by high storage stability.

Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, A, B, and Y are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.

Abstract: Dynamic routing of data to multiple processor complexes. PCI address space is subdivided among a plurality of processor complexes. Translation table entries at each processor complex determine which processor complex is to receive a DMA transfer, thereby enabling routing of DMA data to one I/O hub node while accessing translation table entries at another I/O hub node. Further, interrupt requests may be dynamically routed to multiple processor complexes.

Abstract: The invention relates to a compound of the formula wherein R1, R2, X, Y, n, t and m are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.

Abstract: When decoding an OFDM signal, frame and frequency synchronisation is necessary. The invention shows a method enabling a high accuracy for frame and frequency synchronization, which leads to a very low error rate in comparison to prior art.

Abstract: The present invention is directed to a method for transmitting data via a number of interfaces arranged in parallel. The interfaces respectively have a receiver unit for receiving data packets and for intermediate storage of these data packets and have a transmitter unit for sending data packets. Further, an overall buffer memory is provided for the number of interfaces.

Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of:

Abstract: The present invention relates to prodrugs which are capable of being converted into prodrug intermediates of a cytotoxic or cytostatic drug, by the catalytic action of FAP&agr;, said prodrugs exhibit

Abstract: A process is suggested for checking the catalyst performance in internal-combustion engines, in which by means of detected operating parameters of the internal-combustion engine similar operating conditions are determined. It is suggested to compute from a defined number of measured exhaust gas values during a similar operating condition a statistically backed average exhaust gas value and compare it with a permissible exhaust gas value stored for this operating condition, so that a defective catalyst is recognized in the event of a deviation of the actually determined exhaust gas value from the permissible exhaust gas value.

Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.

Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.

Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.

Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.

Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognized by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions, wherein said prodrug comprises an oligomeric part comprising at least two amino carboxylic residues, and a cytotoxic or cytostatic part, wherein the C-terminal amino carboxylic residue of the oligomeric part is an acyclic amino acid, the nitrogen atom of the amino function thereof is attached to a substituent being different from a hydrogen atom, and the C-terminal carboxy function thereof is linked to the cytotoxic or cytostatic part by an amide bond.

Abstract: The present invention relates to processes for detecting inhibitors of the enzyme N-acetyl-alpha-linked acidic dipeptidase (NAALADase) wherein the enzymatic reaction of a substrate radio-labelled at the C-terminal glutamate group is detected by its binding to fluomicrospheres. The invention further relates to new enzyme substrates and their use in the abovementioned process.